Period	August 2009-December 2021
n: 21	Total tx: 513
	Autologous tx: 373 (MM + Lymphoma)
	MM: 274
	Lymphoma: 99
	Mob regimen(G-CSF/Chemotherapy+G-CSF): 252
	Required third step mob. regimen: 21/373 (7.6%)
Age, median (min-max)	51 (21-66)
Female/Male	6/15 (29%/ 71 %)
Diagnosis
MM:	6 (29%)
Lymphoma:(NHL + HD): (12 + 3)	15 (71%)
Day 1,CD34 + cells count (post-plerixafor)	32 (5.8-92)
Median days of apheresis (day)	2 (2-3)
1	0
2	12 (75 %)
3	1
Total Yield CD34 + x 106 cells/kg
(min-max)	4.72 (1.3-7.17)
Not processed:	4 (19%)
<2 :	2 (9.5 %)
>2-4:	4 (19 %)
>4-6:	11 (52.3%)
Successful mobilization	16 (76 %)
Mobilization failure	5 (24 %)
Patients undergoing transplantation	16 (76 %)
Median time to engraftment (day), (min-max)
Neutrophil> 500: 12 (9-17)	11/16 (69 %)
Platelet > 20 000: 17 (12-30)	8/16 (50 %)
Platelet > 50 000: 35 (17-95)	7/16 (44 %)
Adverse events
Diarrhea	1 (4.7 %)
Nause	1 (4.7 %)